Alejandro Brun

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1372634/publications.pdf

Version: 2024-02-01

73	2,464	172457	214800
papers	citations	29 h-index	47 g-index

77	77	77	2485
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media. Scientific Reports, 2022, 12, 263.	3.3	11
2	An Overview of Veterinary Viral Diseases and Vaccine Technologies. Methods in Molecular Biology, 2022, 2465, 1-26.	0.9	3
3	Using RVFV as a Vector Platform for the Expression of Ruminant Disease Antigens. Methods in Molecular Biology, 2022, 2465, 209-225.	0.9	0
4	Identification of Single Amino Acid Changes in the Rift Valley Fever Virus Polymerase Core Domain Contributing to Virus Attenuation In Vivo. Frontiers in Cellular and Infection Microbiology, 2022, 12, 875539.	3.9	3
5	Development of a multiplex assay for antibody detection in serum against pathogens affecting ruminants. Transboundary and Emerging Diseases, 2021, 68, 1229-1239.	3.0	7
6	The Change P82L in the Rift Valley Fever Virus NSs Protein Confers Attenuation in Mice. Viruses, 2021, 13, 542.	3.3	7
7	Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: In vitro and in vivo. PLoS ONE, 2021, 16, e0256401.	2.5	57
8	A novel Schmallenberg virus subunit vaccine candidate protects IFNAR-/- mice against virulent SBV challenge. Scientific Reports, 2020, 10, 18725.	3.3	4
9	A protective bivalent vaccine against Rift Valley fever and bluetongue. Npj Vaccines, 2020, 5, 70.	6.0	22
10	MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses. Vaccines, 2020, 8, 82.	4.4	13
11	A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus. Molecular Pharmaceutics, 2020, 17, 1608-1620.	4.6	13
12	A Hyper-Attenuated Variant of Rift Valley Fever Virus Generated by a Mutagenic Drug (Favipiravir) Unveils Potential Virulence Markers. Frontiers in Microbiology, 2020, 11, 621463.	3.5	7
13	Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge. PLoS Neglected Tropical Diseases, 2020, 14, e0008942.	3.0	10
14	External quality assessment of Rift Valley fever diagnosis in 17 veterinary laboratories of the Mediterranean and Black Sea regions. PLoS ONE, 2020, 15, e0239478.	2.5	5
15	Title is missing!. , 2020, 14, e0008942.		0
16	Title is missing!. , 2020, 14, e0008942.		0
17	Title is missing!. , 2020, 14, e0008942.		0
18	Title is missing!. , 2020, 14, e0008942.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 14, e0008942.		0
20	Title is missing!. , 2020, 14, e0008942.		0
21	Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	25
22	Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor. Viruses, 2019, 11, 35.	3.3	24
23	Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12Âweeks following vaccination. Veterinary Research, 2018, 49, 21.	3.0	24
24	CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR ^{â^'/â^'} Mice. Journal of Virology, 2018, 92, .	3.4	19
25	DNA vaccination regimes against Schmallenberg virus infection in IFNAR â^'/â^' mice suggest two targets for immunization. Antiviral Research, 2017, 141, 107-115.	4.1	13
26	Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. Journal of Virology, 2017, 91, .	3.4	73
27	Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(â^'/â^') mice conferring protection against serotypes 1 and 4 of bluetongue virus. Antiviral Research, 2017, 142, 55-62.	4.1	13
28	Pathological Characterization Of IFNAR(-/-) Mice Infected With Bluetongue Virus Serotype 4. International Journal of Biological Sciences, 2016, 12, 1448-1460.	6.4	18
29	Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1185-1192.	3.3	100
30	Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Scientific Reports, 2016, 6, 20617.	3.3	98
31	Vaccines and Vaccination for Veterinary Viral Diseases: A General Overview. Methods in Molecular Biology, 2016, 1349, 1-24.	0.9	11
32	Understanding Rift Valley fever: Contributions of animal models to disease characterization and control. Molecular Immunology, 2015, 66, 78-88.	2.2	24
33	Elements Modulating the Prion Species Barrier and Its Passage Consequences. PLoS ONE, 2014, 9, e89722.	2.5	46
34	Generation and application of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein NP and glycoproteins Gn and Gc. Archives of Virology, 2014, 159, 535-546.	2.1	14
35	Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs. Antiviral Research, 2014, 108, 165-172.	4.1	26
36	Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome. Antiviral Research, 2014, 109, 64-67.	4.1	12

#	Article	IF	Citations
37	Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice. Virology Journal, 2013, 10, 349.	3.4	51
38	European ring trial to evaluate ELISAs for the diagnosis of infection with Rift Valley fever virus. Journal of Virological Methods, 2013, 187, 177-181.	2.1	57
39	A Single Immunization with MVA Expressing GnGc Glycoproteins Promotes Epitope-specific CD8+-T Cell Activation and Protects Immune-competent Mice against a Lethal RVFV Infection. PLoS Neglected Tropical Diseases, 2013, 7, e2309.	3.0	46
40	Detection and identification of Rift Valley fever virus in mosquito vectors by quantitative real-time PCR. Virus Research, 2012, 169, 137-143.	2.2	29
41	Bead-based suspension array for simultaneous detection of antibodies against the Rift Valley fever virus nucleocapsid and Gn glycoprotein. Journal of Virological Methods, 2012, 183, 99-105.	2.1	22
42	Lymphoplasmacytic Endotheliitis and Anterior Uveitis in Sheep Infected Experimentally with Rift Valley Fever Virus. Journal of Comparative Pathology, 2012, 146, 40-43.	0.4	6
43	A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNARâ¯'/â¯' mice upon lethal virus challenge. Vaccine, 2011, 29, 4469-4475.	3.8	52
44	Current strategies for subunit and genetic viral veterinary vaccine development. Virus Research, 2011, 157, 1-12.	2.2	63
45	Rift Valley and West Nile Virus Antibodies in Camels, North Africa. Emerging Infectious Diseases, 2011, 17, 2372-2374.	4.3	47
46	Rift Valley Fever: Recent Insights into Pathogenesis and Prevention. Journal of Virology, 2011, 85, 6098-6105.	3.4	101
47	Experimental Infection of Young Adult European Breed Sheep with Rift Valley Fever Virus Field Isolates. Vector-Borne and Zoonotic Diseases, 2010, 10, 689-696.	1.5	60
48	Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization. MAbs, 2010, 2, 275-284.	5.2	37
49	Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNARâ¯'/â¯' mice induced by different DNA vaccination regimens. Vaccine, 2010, 28, 2937-2944.	3.8	66
50	Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine, 2008, 26, 5255-5262.	3.8	28
51	Antigen delivery systems for veterinary vaccine development. Vaccine, 2008, 26, 6508-6528.	3.8	60
52	Altered lymphocyte homeostasis after oral prion infection in mouse. Veterinary Immunology and Immunopathology, 2008, 122, 204-215.	1.2	1
53	Reduced susceptibility to bovine spongiform encephalopathy prions in transgenic mice expressing a bovine PrP with five octapeptide repeats. Journal of General Virology, 2007, 88, 1842-1849.	2.9	18
54	Discrimination of sheep susceptible and resistant to transmissible spongiform encephalopathies by an haplotype specific monoclonal antibody. Journal of Virological Methods, 2007, 145, 169-172.	2.1	6

#	Article	IF	Citations
55	Cell expression of a four extra octarepeat mutated PrPCmodifies cell structure and cell cycle regulation. FEBS Letters, 2006, 580, 4097-4104.	2.8	5
56	Genomics of Viruses. , 2006, , 367-388.		5
57	Distribution of the cellular prion protein (PrPC) in brains of livestock and domesticated species. Acta Neuropathologica, 2006, 112, 587-595.	7.7	13
58	DNA Vaccination Can Break Immunological Tolerance to PrP in Wild-Type Mice and Attenuates Prion Disease after Intracerebral Challenge. Journal of Virology, 2006, 80, 9970-9976.	3.4	36
59	Comparison of Three Monoclonal Antibodies for use in Immunohistochemical Detection of Bovine Spongiform Encephalopathy Protease-Resistant Prion Protein. Journal of Veterinary Diagnostic Investigation, 2006, 18, 106-109.	1.1	5
60	Vertical Transmission of Bovine Spongiform Encephalopathy Prions Evaluated in a Transgenic Mouse Model. Journal of Virology, 2005, 79, 8665-8668.	3.4	34
61	Transgenic mice expressing bovine PrP with a four extra repeat octapeptide insert mutation show a spontaneous, non-transmissible, neurodegenerative disease and an expedited course of BSE infection. FEBS Letters, 2005, 579, 6237-6246.	2.8	36
62	Different Behavior toward Bovine Spongiform Encephalopathy Infection of Bovine Prion Protein Transgenic Mice with One Extra Repeat Octapeptide Insert Mutation. Journal of Neuroscience, 2004, 24, 2156-2164.	3.6	44
63	Subclinical Bovine Spongiform Encephalopathy Infection in Transgenic Mice Expressing Porcine Prion Protein. Journal of Neuroscience, 2004, 24, 5063-5069.	3.6	56
64	Proteinase K enhanced immunoreactivity of the prion protein-specific monoclonal antibody 2A11. Neuroscience Research, 2004, 48, 75-83.	1.9	33
65	Early detection of PrP res in BSE-infected bovine PrP transgenic mice. Archives of Virology, 2003, 148, 677-691.	2.1	119
66	High-yield expression of a viral peptide vaccine in transgenic plants. FEBS Letters, 2001, 488, 13-17.	2.8	66
67	Design and construction of African swine fever virus chimeras incorporating foreign viral epitopes. Archives of Virology, 1999, 144, 1287-1298.	2.1	3
68	The African Swine Fever Virus Proteins p54 and p30 Are Involved in Two Distinct Steps of Virus Attachment and Both Contribute to the Antibody-Mediated Protective Immune Response. Virology, 1998, 243, 461-471.	2.4	175
69	Functionality and Cell Anchorage Dependence of the African Swine Fever Virus GeneA179L, a Viralbcl-2Homolog, in Insect Cells. Journal of Virology, 1998, 72, 10227-10233.	3.4	28
70	High level expression of the major antigenic African swine fever virus proteins p54 and p30 in baculovirus and their potential use as diagnostic reagents. Journal of Virological Methods, 1997, 64, 27-35.	2.1	47
71	African Swine Fever Virus GeneA179L,a Viral Homologue ofbcl-2, Protects Cells from Programmed Cell Death. Virology, 1996, 225, 227-230.	2.4	110
72	An African Swine Fever Virus Gene with Similarity to the T-Lymphocyte Surface Antigen CD2 Mediates Hemadsorption. Virology, 1994, 199, 463-468.	2.4	80

#	Article	IF	Citations
73	Characterization of P30, a highly antigenic membrane and secreted protein of African Swine Fever Virus. Virology, 1992, 189, 368-373.	2.4	101